Search

Your search keyword '"Hungria, Vania"' showing total 682 results
Start Over Author "Hungria, Vania"
682 results on '"Hungria, Vania"'

1. Multiple myeloma

Author

Malard, Florent, Neri, Paola, Bahlis, Nizar J., Terpos, Evangelos, Moukalled, Nour, Hungria, Vania T. M., Manier, Salomon, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

2. COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

Author

Garnica, Marcia, Crusoe, Edvan De Queiroz, Ribeiro, Glaciano, Bittencourt, Rosane, Magalhães, Roberto José Pessoa, Zanella, Karla Richter, Hallack Neto, Abrahão Elias, Lima, Juliana Souza, Solo, Caroline Bonamin, Souza, Emmanuella Graciott, Fernandes, Andre Magalhaes, Maiolino, Angelo, and Hungria, Vania

Published
2024
Full Text
View/download PDF

3. Brazilian Real-Life Experience of Multiple Myeloma (MMyBRAve): Improvement in Outcomes, But Remaining Diagnostic and Therapeutic Gaps

Author

Hungria, Vania, Bittencourt, Rosane Isabel, Martinez, Gracia Aparecida, Santos, Juliana de Andrade, de Almeida, Denise Ramos, Figueiredo, Vera Lucia de Piratininga, de Farias, Danielle Leão Cordeiro, Zanella, Karla Richter, Muniz, Larissa Barchi, Senra, Juliana Tosta, Abreu, Rodrigo Martins, and Mattos, Éderson Roberto

Published
2024
Full Text
View/download PDF

4. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Author

Dimopoulos, Meletios Athanasios, Hungria, Vania T M, Radinoff, Atanas, Delimpasi, Sosana, Mikala, Gabor, Masszi, Tamas, Li, Jian, Capra, Marcelo, Maiolino, Angelo, Pappa, Vasiliki, Chraniuk, Dominik, Osipov, Iurii, Leleu, Xavier, Low, Michael, Matsumoto, Morio, Sule, Neal, Li, Mary, McKeown, Astrid, He, Wei, Bright, Shelley, Currie, Brooke, Perera, Sue, Boyle, Julia, Roy-Ghanta, Sumita, Opalinska, Joanna, and Weisel, Katja

Published
2023
Full Text
View/download PDF

8. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Author

Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, van Rhee, Frits, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hájek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesus G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, and Chari, Ajai

Published
2023
Full Text
View/download PDF

9. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Author

Costello, Caitlin, Davies, Faith E, Cook, Gordon, Vela-Ojeda, Jorge, Omel, Jim, Rifkin, Robert M, Berdeja, Jesus, Puig, Noemi, Usmani, Saad Z, Weisel, Katja, Zonder, Jeffrey A, Terpos, Evangelos, Spencer, Andrew, Leleu, Xavier, Boccadoro, Mario, Thompson, Michael A, Romanus, Dorothy, Stull, Dawn M, and Hungria, Vania

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Comparative Effectiveness Research, Hematology, Orphan Drug, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Follow-Up Studies, Humans, International Agencies, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Prospective Studies, Quality of Life, Treatment Outcome, Young Adult, multiple myeloma, observational study, treatment, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

With the introduction of new drugs with different mechanisms of action, multiple myeloma (MM) patients' outcomes have improved. However, the efficacy seen in clinical trials is often not seen in real-world settings and data on the effectiveness of MM therapies are needed. INSIGHT MM is a prospective, global, non-interventional, observational study that is enrolling approximately 4200 patients with newly diagnosed or relapsed/refractory MM, making it the largest study of its kind to date. The study aims to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapies chosen, clinical outcomes (response, treatment duration, time-to-next-therapy, progression-free and overall survival), safety, healthcare resource utilization and quality of life. One interim analysis has been conducted to date; current accrual is approximately 3094 patients. Trial registration number: NCT02761187.

Published
2019

10. Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira – 2022. Part I

Author

Maiolino, Angelo, Crusoé, Edvan de Queiroz, Martinez, Gracia Aparecida, Braga, Walter Moisés Tobias, de Farias, Danielle Leão Cordeiro, Bittencourt, Rosane Isabel, Neto, Jorge Vaz Pinto, Ribeiro, Glaciano Nogueira, Bernardo, Wanderley Marques, Tristão, Luca, Magalhaes, Roberto J.P., and Hungria, Vânia Tietsche de Moraes

Published
2022
Full Text
View/download PDF

11. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Author

Cavo, Michele, San-Miguel, Jesus, Usmani, Saad Z., Weisel, Katja, Dimopoulos, Meletios A., Avet-Loiseau, Hervé, Paiva, Bruno, Bahlis, Nizar J., Plesner, Torben, Hungria, Vania, Moreau, Philippe, Mateos, Maria-Victoria, Perrot, Aurore, Iida, Shinsuke, Facon, Thierry, Kumar, Shaji, van de Donk, Niels W.C.J., Sonneveld, Pieter, Spencer, Andrew, Krevvata, Maria, Heuck, Christoph, Wang, Jianping, Ukropec, Jon, Kobos, Rachel, Sun, Steven, Qi, Mia, and Munshi, Nikhil

Published
2022
Full Text
View/download PDF

13. Patient-reported outcomes (PROs) from the DREAMM-7 randomized phase 3 study comparing belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma (RRMM).

Author

Hungria, Vania, primary, Robak, Pawel, additional, Hus, Marek, additional, Fu, Chengcheng, additional, Zherebtsova, Vera, additional, Ward, Christopher, additional, de Almeida, Ana Carolina, additional, Ho, P. Joy, additional, Hajek, Roman, additional, Cerchione, Claudio, additional, Pirooz, Nicholas, additional, McKeown, Astrid, additional, Baig, Hena, additional, Eccersley, Lydia, additional, Pompilus, Farrah, additional, McNamara, Simon, additional, Lin, Chee Paul, additional, Roy-Ghanta, Sumita, additional, Opalinska, Joanna, additional, and Mateos, Maria-Victoria, additional

Published
2024
Full Text
View/download PDF

16. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Author

Moreau, Philippe, Kumar, Shaji K, San Miguel, Jesús, Davies, Faith, Zamagni, Elena, Bahlis, Nizar, Ludwig, Heinz, Mikhael, Joseph, Terpos, Evangelos, Schjesvold, Fredrik, Martin, Thomas, Yong, Kwee, Durie, Brian G M, Facon, Thierry, Jurczyszyn, Artur, Sidana, Surbhi, Raje, Noopur, van de Donk, Niels, Lonial, Sagar, Cavo, Michele, Kristinsson, Sigurdur Y, Lentzsch, Suzanne, Hajek, Roman, Anderson, Kenneth C, João, Cristina, Einsele, Hermann, Sonneveld, Pieter, Engelhardt, Monika, Fonseca, Rafael, Vangsted, Annette, Weisel, Katja, Baz, Rachid, Hungria, Vania, Berdeja, Jesus G, Leal da Costa, Fernando, Maiolino, Angelo, Waage, Anders, Vesole, David H, Ocio, Enrique M, Quach, Hang, Driessen, Christoph, Bladé, Joan, Leleu, Xavier, Riva, Eloisa, Bergsagel, Peter Leif, Hou, Jian, Chng, Wee Joo, Mellqvist, Ulf-Henrik, Dytfeld, Dominik, Harousseau, Jean-Luc, Goldschmidt, Hartmut, Laubach, Jacob, Munshi, Nikhil C, Gay, Francesca, Beksac, Meral, Costa, Luciano J, Kaiser, Martin, Hari, Parameswaran, Boccadoro, Mario, Usmani, Saad Z, Zweegman, Sonja, Holstein, Sarah, Sezer, Orhan, Harrison, Simon, Nahi, Hareth, Cook, Gordon, Mateos, Maria-Victoria, Rajkumar, S Vincent, Dimopoulos, Meletios A, and Richardson, Paul G

Published
2021
Full Text
View/download PDF

17. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil.

Author

Hungria, Vania, Sureda, Anna, Campelo, Garcia Rosario, Salvino, Marco Aurélio, and Ramasamy, Karthik

Subjects
*TREATMENT of lung tumors, *MULTIPLE myeloma treatment, *HODGKIN'S disease treatment, *INTERPROFESSIONAL relations, *CANCER patient medical care, *CLINICAL medicine research, *CONFERENCES & conventions, *ONCOLOGISTS, *DRUG development
Abstract

Simple Summary: The first Onco Summit: The Latin American (LATAM) Chapter was held from 19–20 May 2023, in Rio de Janeiro, Brazil. This educational initiative aimed to discuss the current challenges in cancer care, both globally and in LATAM, and foster the exchange of best practices to address these challenges. The Summit brought together more than 30 international and regional experts and more than 300 oncology specialists to deliberate on the advancements and barriers in oncology, with a focus on strategies tailored to the specific needs of LATAM. This report provides an overview of the key discussions among cancer specialists at the Summit. The Onco Summit 2023: The Latin American (LATAM) Chapter took place over two days, from 19–20 May 2023, in Brazil. The event aimed to share the latest updates across various oncology disciplines, address critical clinical challenges, and exchange best practices to ensure optimal patient treatment. More than 30 international and regional speakers and more than 300 oncology specialists participated in the Summit. The Summit discussions centered on common challenges and therapeutic advances in cancer care, with a specific focus on the unique obstacles faced in LATAM and examples of adaptable strategies to address these challenges. The Summit also facilitated the establishment of a network of oncologists, hematologists, and scientists in LATAM, enabling collaboration to improve cancer care, both in this region and globally, through drug development and clinical research. This report summarizes the key discussions from the Summit for the global and LATAM oncology community. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.

Author

Lee, Hans C., Ramasamy, Karthik, Macro, Margaret, Davies, Faith E., Abonour, Rafat, van Rhee, Frits, Hungria, Vania T. M., Puig, Noemi, Ren, Kaili, Silar, Jiri, Enwemadu, Victoria, Cherepanov, Dasha, and Leleu, Xavier

Subjects
MULTIPLE myeloma, PROTEASOME inhibitors, LENALIDOMIDE, BORTEZOMIB, REFRACTORY materials, PROGRESSION-free survival
Abstract

Objectives: To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib–lenalidomide–dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM). Methods: INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA‐IXA, and REMIX. Results: Overall, 391/100/68 were lenalidomide‐naïve/−exposed/−refractory and 37/411/110 were PI‐naïve/−exposed/−refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression‐free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide‐naïve/exposed/refractory patients. Median DOT and PFS in PI‐naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable. Conclusion: IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide‐ and/or PI‐nonrefractory versus refractory patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

20. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Author

Kumar, Shaji K, Harrison, Simon J, Cavo, Michele, de la Rubia, Javier, Popat, Rakesh, Gasparetto, Cristina, Hungria, Vania, Salwender, Hans, Suzuki, Kenshi, Kim, Inho, Punnoose, Elizabeth A, Hong, Wan-Jen, Freise, Kevin J, Yang, Xiaoqing, Sood, Anjla, Jalaluddin, Muhammad, Ross, Jeremy A, Ward, James E, Maciag, Paulo C, and Moreau, Philippe

Published
2020
Full Text
View/download PDF

21. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

Author

Mateos, Maria-Victoria, Sonneveld, Pieter, Hungria, Vania, Nooka, Ajay K., Estell, Jane A., Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Medvedova, Eva, Weisel, Katja, Chiu, Christopher, Schecter, Jordan M., Amin, Himal, Qin, Xiang, Ukropec, Jon, Kobos, Rachel, and Spencer, Andrew

Published
2020
Full Text
View/download PDF

23. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial

Author

Mateos, Maria-Victoria, Nahi, Hareth, Legiec, Wojciech, Grosicki, Sebastian, Vorobyev, Vladimir, Spicka, Ivan, Hungria, Vania, Korenkova, Sibirina, Bahlis, Nizar, Flogegard, Max, Bladé, Joan, Moreau, Philippe, Kaiser, Martin, Iida, Shinsuke, Laubach, Jacob, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Clemens, Pamela L, Masterson, Tara, Lantz, Kristen, O'Rourke, Lisa, Heuck, Christoph, Qin, Xiang, Parasrampuria, Dolly A, Yuan, Zhilong, Xu, Steven, Qi, Ming, and Usmani, Saad Z

Published
2020
Full Text
View/download PDF

25. Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation

Author

Crusoe, Edvan De Queiroz, Higashi, Fabiana, Martinez, Gracia, Bittencourt, Rosane, Pinto Neto, Jorge Vaz, Sousa, Lais, Santucci, Rodrigo, Magalhães, Roberto José Pessoa, Colli, Gilberto, Nunes, Renata Ferreira Marques, Ribeiro, Glaciano, Nicacio, Jandir, Zanella, Karla Richter, Kutner, Jose Mauro, Magalhaes, Andre, Leao, Danielle, Hallack Neto, Abrahão Elias, Braga, Walter, Souza, Emanuella G, Guimaraes, Antonio Julio A.M., Durigon, Giovanna Steffenello, Laks, Dani, Maiolino, Angelo, and Hungria, Vania Tietsche de Moraes

Published
2020
Full Text
View/download PDF

26. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).

Author

Mateos, Maria-Victoria, primary, Robak, Pawel, additional, Hus, Marek, additional, Xia, Zhongjun, additional, Zherebtsova, Vera, additional, Ward, Christopher, additional, Ho, P. Joy, additional, Hajek, Roman, additional, Kim, Kihyun, additional, Dimopoulos, Meletios A., additional, Cerchione, Claudio, additional, Riccio, Antonio, additional, McKeown, Astrid, additional, Rogers, Rachel, additional, Baig, Hena, additional, Eccersley, Lydia, additional, Roy-Ghanta, Sumita, additional, Opalinska, Joanna, additional, and Hungria, Vania, additional

Published
2024
Full Text
View/download PDF

27. A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the Mmybrave Multicenter Observational Study

Author

Hungria, Vania Tietsche de Moraes, primary, Bittencourt, Rosane Isabel, additional, Martinez, Gracia Aparecida, additional, Santos, Juliana de Andrade, additional, Almeida, Denise Ramos de, additional, Figueiredo, Vera Lucia de Piratininga, additional, Farias, Danielle Leão Cordeiro de, additional, Zanella, Karla Richter, additional, Muniz, Larissa Barchi, additional, Senra, Juliana Tosta, additional, Abreu, Rodrigo Martins, additional, and Mattos, Ederson Roberto, additional

Published
2024
Full Text
View/download PDF

28. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

Author

Usmani, Saad Z., Mateos, Maria-Victoria, Hungria, Vania, Iida, Shinsuke, Bahlis, Nizar J., Nahi, Hareth, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Fastenau, John, Slavcev, Mary, Heuck, Christoph, Qin, Xiang, Pei, Huiling, Masterson, Tara, Lantz, Kristen, and Gries, Katharine S.

Published
2021
Full Text
View/download PDF

29. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Author

Costa, Luciano J., Derman, Benjamin A., Bal, Susan, Sidana, Surbhi, Chhabra, Saurabh, Silbermann, Rebecca, Ye, Jing C., Cook, Gordon, Cornell, Robert F., Holstein, Sarah A., Shi, Qian, Omel, James, Callander, Natalie S., Chng, Wee Joo, Hungria, Vania, Maiolino, Angelo, Stadtmauer, Edward, Giralt, Sergio, Pasquini, Marcelo, Jakubowiak, Andrzej J., Morgan, Gareth J., Krishnan, Amrita, Jackson, Graham H., Mohty, Mohamad, Mateos, Maria Victoria, Dimopoulos, Meletious A., Facon, Thierry, Spencer, Andrew, Miguel, Jesus San, Hari, Parameswaran, Usmani, Saad Z., Manier, Salomon, McCarthy, Phillip, Kumar, Shaji, Gay, Francesca, and Paiva, Bruno

Published
2021
Full Text
View/download PDF

32. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries

Author

Pessoa de Magalhães Filho, Roberto José, Crusoe, Edvan, Riva, Eloisa, Bujan, Willen, Conte, Guilhermo, Navarro Cabrera, Juan Ramon, Garcia, Diana Katerine, Vega, Guilhermo Quintero, Macias, Jose, Oliveros Alvear, Jose Willian, Royg, Mercedes, Neves, Lidiane Andino, Lopez Dopico, Jose Luis, Espino, German, Ortiz, Douglas Rosales, Socarra, Zurelis, Fantl, Dorotea, Ruiz-Arguelles, Guillermo J., Maiolino, Angelo, Hungria, Vania Tietsche de Moraes, Harousseau, Jean-Luc, and Durie, Brian

Published
2019
Full Text
View/download PDF

33. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries

Author

Hungria, Vania T. M., Lee, Jae Hoon, Maiolino, Angelo, de Queiroz Crusoe, Edvan, Martinez, Gracia, Bittencourt, Rosane, Duarte, Gislaine Oliveira, Fantl, Dorotea Beatriz, Navarro, Juan Ramon, Conte, Guillermo, Gomez-Almaguer, David, Ruiz-Argüelles, Guillermo J., Kim, Kihyun, Shimizu, Kazuyuki, Chen, Wenming, Huang, Shang-YI, Chng, Wee-Joo, Chim, Chor Sang, Nawarawong, Weerasak, and Durie, Brian

Published
2019
Full Text
View/download PDF

34. COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

Author

Garnica, Marcia, primary, Crusoe, Edvan De Queiroz, additional, Ribeiro, Glaciano, additional, Bittencourt, Rosane, additional, Magalhães, Roberto José Pessoa, additional, Zanella, Karla Richter, additional, Hallack Neto, Abrahão Elias, additional, Lima, Juliana Souza, additional, Solo, Caroline Bonamin, additional, Souza, Emmanuella Graciott, additional, Fernandes, Andre Magalhaes, additional, Maiolino, Angelo, additional, and Hungria, Vania, additional

Published
2023
Full Text
View/download PDF

35. P-052 LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)

Author

Weisel, Katja, primary, Hungria, Vania, additional, Quach, Hang, additional, Yoon, Sung-Soo, additional, Rodriguez-Otero, Paula, additional, Sinha, Arijit, additional, Boyapati, Anita, additional, Lyon, Charlotte, additional, Moore, Vygngley, additional, Inocencio, Tim, additional, Harnett, James, additional, Chi, Lei, additional, Lorenc, Karen Rodriguez, additional, Kroog, Glenn, additional, and Voorhees, Peter, additional

Published
2023
Full Text
View/download PDF

36. MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Author

Weisel, Katja, primary, Hungria, Vania T.M., additional, Radinoff, Atanas, additional, Delimpasi, Sosana, additional, Gabor, Mikala, additional, Masszi, Tamas, additional, Li, Jian, additional, Capra, Marcelo, additional, Matsumoto, Morio, additional, Sule, Neal, additional, Li, Mary, additional, McKeown, Astrid, additional, He, Wei, additional, Bright, Shelley, additional, Currie, Brooke, additional, Boyle, Julia, additional, Opalinska, Joanna, additional, and Dimopoulos, Meletios Athanasios, additional

Published
2023
Full Text
View/download PDF

37. P-140 Multiple myeloma in Latin America cancer registry: the MYLACRE study

Author

Hungria, Vania, primary, Gaiolla, Rafael, additional, Galvez, Kenny, additional, Remaggi, Guillermina, additional, Schutz, Natalia, additional, Bittencourt, Rosane, additional, Maiolino, Angelo, additional, Quintero, Guillermo, additional, Cugliari, Maria, additional, Braga, Walter Tobias, additional, Villarim, Carolina, additional, Crusoé, Edvan, additional, Enrico, Alicia, additional, Pei, Huiling, additional, Fernandez, Mariana, additional, Saes, Jaqueline, additional, and Trufelli, Damila, additional

Published
2023
Full Text
View/download PDF

38. MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

Author

Hungria, Vania, primary, Weisel, Katja, additional, Currie, Brooke, additional, Perera, Sue, additional, Sule, Neal, additional, He, Wei, additional, Davy, Katherine, additional, McKeown, Astrid, additional, Sapra, Sandhya, additional, Nelsen, Linda, additional, Li, Mary, additional, Barale, Sophie, additional, Boyle, Julia, additional, McPoyle, Kaytlyn, additional, and Dimopoulos, Meletios Athanasios, additional

Published
2023
Full Text
View/download PDF

39. POSTER: MM-509 A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM3)

Author

Weisel, Katja, primary, Hungria, Vania T.M., additional, Radinoff, Atanas, additional, Delimpasi, Sosana, additional, Gabor, Mikala, additional, Masszi, Tamas, additional, Li, Jian, additional, Capra, Marcelo, additional, Matsumoto, Morio, additional, Sule, Neal, additional, Li, Mary, additional, McKeown, Astrid, additional, He, Wei, additional, Bright, Shelley, additional, Currie, Brooke, additional, Boyle, Julia, additional, Opalinska, Joanna, additional, and Dimopoulos, Meletios Athanasios, additional

Published
2023
Full Text
View/download PDF

40. POSTER: MM-510 Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study

Author

Hungria, Vania, primary, Weisel, Katja, additional, Currie, Brooke, additional, Perera, Sue, additional, Sule, Neal, additional, He, Wei, additional, Davy, Katherine, additional, McKeown, Astrid, additional, Sapra, Sandhya, additional, Nelsen, Linda, additional, Li, Mary, additional, Barale, Sophie, additional, Boyle, Julia, additional, McPoyle, Kaytlyn, additional, and Dimopoulos, Meletios Athanasios, additional

Published
2023
Full Text
View/download PDF

41. P954: MULTIPLE MYELOMA IN LATIN AMERICA CANCER REGISTRY: THE MYLACRE STUDY

Author

Hungria, Vania, primary, Gaiolla, Rafael, additional, Galvez, Kenny, additional, Remaggi, Guillermina, additional, Schutz, Natalia, additional, Bittencourt, Rosane, additional, Maiolino, Angelo, additional, Quintero, Guillermo, additional, Silvana Cugliari, Maria, additional, Moises Tobias, Walter, additional, Colaco Villarim, Carolina, additional, Crusoe, Edvan, additional, Ines Enrico, Alicia, additional, Pei, Huiling, additional, Fernandez, Mariana, additional, Saes, Jaqueline, additional, and Trufelli, Damila, additional

Published
2023
Full Text
View/download PDF

42. S199: A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF SINGLE AGENT BELANTAMAB MAFODOTIN VS POMALIDOMIDE PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (DREAMM-3)

Author

Dimopoulos, Meletios A., primary, Hungria, Vania, additional, Radinoff, Atanas, additional, Delimpasi, Sosana, additional, Mikala, Gabor, additional, Masszi, Tamas, additional, LI, Jian, additional, Capra, Marcelo Eduardo, additional, Matsumoto, Morio, additional, Sule, Neal, additional, LI, Mary, additional, Mckeown, Astrid, additional, He, Wei, additional, Bright, Shelley, additional, Currie, Brooke, additional, Boyle, Julia, additional, Opalinska, Joanna, additional, and Weisel, Katja, additional

Published
2023
Full Text
View/download PDF

43. P964: PATIENT (PT)-REPORTED OUTCOMES IN PTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH BELANTAMAB MAFODOTIN (BELAMAF) VS POMALIDOMIDE/LOW DOSE DEXAMETHASONE (PD) IN THE DREAMM-3 STUDY

Author

Hungria, Vania, primary, Weisel, Katja, additional, Currie, Brooke, additional, Perera, Sue, additional, Sule, Neal, additional, He, Wei, additional, Mckeown, Astrid, additional, Sapra, Sandhya, additional, Nelsen, Linda, additional, LI, Mary, additional, Barale, Sophie, additional, Boyle, Julia, additional, Mcpoyle, Kaytlyn, additional, and Dimopoulos, Meletios A., additional

Published
2023
Full Text
View/download PDF

44. PB2133: TRIAL IN PROGRESS: LINKER-MM3, A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF LINVOSELTAMAB VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Author

Weisel, Katja, primary, Hungria, Vania, additional, Quach, Hang, additional, Yoon, Sung-Soo, additional, Rodríguez-Otero, Paula, additional, Kroog, Glenn, additional, Sinha, Arijit, additional, Boyapati, Anita, additional, Lyon, Charlotte, additional, Lorenc, Karen Rodriguez, additional, Inocencio, Timothy, additional, Harnett, James, additional, Chi, Lei, additional, Moore, Vygngley, additional, and Voorhees, Peter, additional

Published
2023
Full Text
View/download PDF

45. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Goldschmidt, Hartmut, Niesvizky, Ruben, Joshua, Douglas, Chng, Wee-Joo, Oriol, Albert, Orlowski, Robert Z, Ludwig, Heinz, Facon, Thierry, Hajek, Roman, Weisel, Katja, Hungria, Vania, Minuk, Leonard, Feng, Shibao, Zahlten-Kumeli, Anita, Kimball, Amy S, and Moreau, Philippe

Published
2017
Full Text
View/download PDF

46. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Author

Weisel, Katja, Spencer, Andrew, Lentzsch, Suzanne, Avet-Loiseau, Hervé, Mark, Tomer M., Spicka, Ivan, Masszi, Tamas, Lauri, Birgitta, Levin, Mark-David, Bosi, Alberto, Hungria, Vania, Cavo, Michele, Lee, Je-Jung, Nooka, Ajay, Quach, Hang, Munder, Markus, Lee, Cindy, Barreto, Wolney, Corradini, Paolo, Min, Chang-Ki, Chanan-Khan, Asher A., Horvath, Noemi, Capra, Marcelo, Beksac, Meral, Ovilla, Roberto, Jo, Jae-Cheol, Shin, Ho-Jin, Sonneveld, Pieter, Casneuf, Tineke, DeAngelis, Nikki, Amin, Himal, Ukropec, Jon, Kobos, Rachel, and Mateos, Maria-Victoria

Published
2020
Full Text
View/download PDF

47. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR):A Randomized, Open-Label, Phase III Trial

Author

Sonneveld, Pieter, Chanan-Khan, Asher, Weisel, Katja, Nooka, Ajay K., Masszi, Tamas, Beksac, Meral, Spicka, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria-Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Spencer, Andrew, Sonneveld, Pieter, Chanan-Khan, Asher, Weisel, Katja, Nooka, Ajay K., Masszi, Tamas, Beksac, Meral, Spicka, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria-Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, and Spencer, Andrew

Abstract

PURPOSE At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). METHODS CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. RESULTS At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). CONCLUSION D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT0213

Published
2023

48. Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial

Author

Janssen Research and Development, Sonneveld, Pieter, Chanan-Khan, Asher A., Weisel, Katja C., Nooka, Ajay, Masszi, Tamas, Beksac, Meral, Špička, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, Spencer, Andrew, Janssen Research and Development, Sonneveld, Pieter, Chanan-Khan, Asher A., Weisel, Katja C., Nooka, Ajay, Masszi, Tamas, Beksac, Meral, Špička, Ivan, Hungria, Vania, Munder, Markus, Mateos, Maria Victoria, Mark, Tomer M., Levin, Mark-David, Ahmadi, Tahamtan, Qin, Xiang, Garvin Mayo, Wendy, Gai, Xue, Carey, Jodi, Carson, Robin, and Spencer, Andrew

Abstract

[Purpose]: At the primary analysis of CASTOR (median follow-up, 7.4 months), daratumumab plus bortezomib and dexamethasone (D-Vd) significantly prolonged progression-free survival versus bortezomib and dexamethasone (Vd) alone in relapsed or refractory multiple myeloma (RRMM). We report updated efficacy and safety results at the final analysis for overall survival (OS). [Methods]: CASTOR was a multicenter, randomized, open-label, phase III study during which eligible patients with ≥ 1 line of prior therapy were randomly assigned to Vd (up to eight cycles) with or without daratumumab (until disease progression). After positive primary analysis and protocol amendment, patients receiving Vd were offered daratumumab monotherapy after disease progression. [Results]: At a median (range) follow-up of 72.6 months (0.0-79.8), significant OS benefit was observed with D-Vd (hazard ratio, 0.74; 95% CI, 0.59 to 0.92; P = .0075). Median OS was 49.6 months with D-Vd versus 38.5 months with Vd. Prespecified subgroup analyses demonstrated an OS advantage with D-Vd versus Vd for most subgroups, including patients age ≥ 65 years and patients with one or two prior lines of therapy, International Staging System stage III disease, high-risk cytogenetic abnormalities, and prior bortezomib treatment. The most common (≥ 10%) grade 3/4 treatment-emergent adverse events with D-Vd versus Vd were thrombocytopenia (46.1% v 32.9%), anemia (16.0% v 16.0%), neutropenia (13.6% v 4.6%), lymphopenia (10.3% v 2.5%), and pneumonia (10.7% v 10.1%). [Conclusion]: D-Vd significantly prolonged OS in patients with RRMM, with the greatest OS benefit observed in patients with one prior line of therapy. To our knowledge, our results, together with the OS benefit observed with daratumumab plus lenalidomide and dexamethasone in the phase III POLLUX study, demonstrate for the first time an OS benefit with daratumumab-containing regimens in RRMM (ClinicalTrials.gov identifier: NCT02136134 [CASTOR]).

Published
2023

49. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients

Author

Millennium Pharmaceuticals, Takeda Pharmaceutical Company, Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, Rhee, Frits van, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hajek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesús G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, Chari, Ajai, Millennium Pharmaceuticals, Takeda Pharmaceutical Company, Thompson, Michael A., Boccadoro, Mario, Leleu, Xavier, Vela-Ojeda, Jorge, Rhee, Frits van, Weisel, Katja C., Rifkin, Robert M., Usmani, Saad Z., Hajek, Roman, Cook, Gordon, Abonour, Rafat, Armour, Mira, Morgan, Kathryn E., Yeh, Su-Peng, Costello, Caitlin L., Berdeja, Jesús G., Davies, Faith E., Zonder, Jeffrey A., Lee, Hans C., Omel, Jim, Spencer, Andrew, Terpos, Evangelos, Hungria, Vania T.M., Puig, Noemi, Fu, Chengcheng, Ferrari, Renda H., Ren, Kaili, Stull, Dawn Marie, and Chari, Ajai

Abstract

[Background]: Infections are a common reason for hospitalization and death in multiple myeloma (MM). Although pneumococcal vaccination (PV) and influenza vaccination (FV) are recommended for MM patients, data on vaccination status and outcomes are limited in MM., [Materials and Methods]: We utilized data from the global, prospective, observational INSIGHT MM study to analyze FV and PV rates and associated outcomes of patients with MM enrolled 2016-2019., [Results]: Of the 4307 patients enrolled, 2543 and 2500 had study-entry data on FV and PV status. Overall vaccination rates were low (FV 39.6%, PV 30.2%) and varied by region. On separate multivariable analyses of overall survival (OS) by Cox model, FV in the prior 2 years and PV in the prior 5 years impacted OS (vs. no vaccination; FV: HR, 0.73; 95% CI, 0.60-0.90; P = .003; PV: HR, 0.51; 95% CI, 0.42-0.63; P < .0001) when adjusted for age, region, performance status, disease stage, cytogenetics at diagnosis, MM symptoms, disease status, time since diagnosis, and prior transplant. Proportions of deaths due to infections were lower among vaccinated versus non-vaccinated patients (FV: 9.8% vs. 15.3%, P = .142; PV: 9.9% vs. 18.0%, P = .032). Patients with FV had generally lower health resource utilization (HRU) versus patients without FV; patients with PV had higher or similar HRU versus patients without PV., [Conclusion]: Vaccination is important in MM and should be encouraged. Vaccination status should be recorded in prospective clinical trials as it may affect survival. This trial was registered at www.clinicaltrials.gov as #NCT02761187.

Published
2023

50. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Author

San-Miguel, Jesús F, Hungria, Vania T M, Yoon, Sung-Soo, Beksac, Meral, Dimopoulos, Meletios A, Elghandour, Ashraf, Jedrzejczak, Wieslaw W, Günther, Andreas, Nakorn, Thanyaphong N, Siritanaratkul, Noppadol, Schlossman, Robert L, Hou, Jian, Moreau, Philippe, Lonial, Sagar, Lee, Jae H, Einsele, Hermann, Sopala, Monika, Bengoudifa, Bourras-Rezki, Binlich, Florence, and Richardson, Paul G

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results